The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued products.
GlobalData tracks 30 drugs in development for B-Cell Chronic Lymphocytic Leukemia by 29 companies/universities/institutes. The top development phase for B-Cell Chronic Lymphocytic Leukemia is phase i with 12 drugs in that stage. The B-Cell Chronic Lymphocytic Leukemia pipeline has 23 drugs in development by companies and seven by universities/ institutes. Some of the companies in the B-Cell Chronic Lymphocytic Leukemia pipeline products market are: Bristol-Myers Squibb, Biosplice Therapeutics and Baylor College of Medicine.
The key targets in the B-Cell Chronic Lymphocytic Leukemia pipeline products market include Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2), and Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1).
The key mechanisms of action in the B-Cell Chronic Lymphocytic Leukemia pipeline product include Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19) with 13 drugs in Phase II. The B-Cell Chronic Lymphocytic Leukemia pipeline products include five routes of administration with the top ROA being Intravenous and four key molecule types in the B-Cell Chronic Lymphocytic Leukemia pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
B-Cell Chronic Lymphocytic Leukemia overview
B-cell chronic lymphocytic leukemia is a type of slow-growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms, or in the groin; pain or discomfort under the ribs on the left side due to an enlarged spleen; frequent or repeated infections and slow healing, due to a lack of normal white blood cells; excessive sweating at night; and unintentional weight loss. Treatment includes chemotherapy and radiation.
For a complete picture of B-Cell Chronic Lymphocytic Leukemia’s pipeline drug market, buy the report here.
Source link
#BCell #Chronic #Lymphocytic #Leukemia #drugs #development
